Abstract
Cancers of the colon and rectum are a leading cause of cancer-related death in the United States and worldwide. The 5-year survival rates, in general, have improved over time for patients with colon cancer due to evolving preventative strategies, improved screening techniques and the recent development of more effective therapeutic agents. Unfortunately, the treatment for patients with locally advanced rectal cancer remains less studied. This review will highlight recently reported trials evaluating pre-operative versus post-operative treatment strategies. A discussion of ongoing trials incorporating conventional chemotherapy and radiation will be included as well as trials planned or ongoing that incorporate radiation and the targeted agents. Further work is required regarding the rational integration of these targeted agents and the optimal selection of patients that will most likely benefit.
Keywords: Total Mesorectal Excision (TME), Abdominoperineal resection (APR), Adjuvant radiotherapy, Postoperative Chemoradiation, flourouracil (5 FU)
Reviews on Recent Clinical Trials
Title: Rectal Cancer: Adjuvant Therapy and New Directions
Volume: 2 Issue: 1
Author(s): Kevin P. McMullen, Charles Matthews and A. William Blackstock
Affiliation:
Keywords: Total Mesorectal Excision (TME), Abdominoperineal resection (APR), Adjuvant radiotherapy, Postoperative Chemoradiation, flourouracil (5 FU)
Abstract: Cancers of the colon and rectum are a leading cause of cancer-related death in the United States and worldwide. The 5-year survival rates, in general, have improved over time for patients with colon cancer due to evolving preventative strategies, improved screening techniques and the recent development of more effective therapeutic agents. Unfortunately, the treatment for patients with locally advanced rectal cancer remains less studied. This review will highlight recently reported trials evaluating pre-operative versus post-operative treatment strategies. A discussion of ongoing trials incorporating conventional chemotherapy and radiation will be included as well as trials planned or ongoing that incorporate radiation and the targeted agents. Further work is required regarding the rational integration of these targeted agents and the optimal selection of patients that will most likely benefit.
Export Options
About this article
Cite this article as:
McMullen P. Kevin, Matthews Charles and William Blackstock A., Rectal Cancer: Adjuvant Therapy and New Directions, Reviews on Recent Clinical Trials 2007; 2 (1) . https://dx.doi.org/10.2174/157488707779318071
DOI https://dx.doi.org/10.2174/157488707779318071 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Current Cancer Drug Targets Cyclooxygenase-2: Potential Role in Regulation of Drug Efflux and Multidrug Resistance Phenotype
Current Pharmaceutical Design Nanoparticulate Drug Delivery System to Overcome the Limitations of Conventional Curcumin in the Treatment of Various Cancers: A Review
Drug Delivery Letters Hyaluronan and Hyaluronan Synthases: Potential Therapeutic Targets in Cancer
Current Drug Targets - Cardiovascular & Hematological Disorders Patent Analysis as a Tool for Research Planning: Study on Natural Based Therapeutics Against Cancer Stem Cells
Recent Patents on Anti-Cancer Drug Discovery Endometriosis and Perinatal Outcome - A Systematic Review of the Literature
Current Women`s Health Reviews Advances in the Development of Multimodal Imaging Agents for Nuclear/Near-infrared Fluorescence Imaging
Current Medicinal Chemistry Dietary Fish Oil Reduces Colon Cancer Risk
Current Organic Chemistry CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Sirtuin-1 and HIV-1: An Overview
Current Drug Targets Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1
Current Drug Metabolism Berberine Interfered with Breast Cancer Cells Metabolism, Balancing Energy Homeostasis
Anti-Cancer Agents in Medicinal Chemistry Physiological Roles of Glycogen Synthase Kinase-3: Potential as a Therapeutic Target for Diabetes and Other Disorders
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Serum Interleukin Levels and Insulin Resistance in Major Depressive Disorder
CNS & Neurological Disorders - Drug Targets Clinical Pharmacokinetic and Metabolism of PET Radiotracers for Imaging P-glycoprotein in Chemoresistant Tumor of Colorectal Cancer
Current Drug Metabolism Multidimensional Role of Inulin as Synbiotic, Drug Carrier and Synergistic Adjuvant for the Colonic Delivery of 5-FU
Drug Delivery Letters Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia
Current Pharmaceutical Design Novel Drugs for Neuroblastoma
Drug Design Reviews - Online (Discontinued) miR-137 Suppresses the Phosphorylation of AKT and Improves the Dexamethasone Sensitivity in Multiple Myeloma Cells Via Targeting MITF
Current Cancer Drug Targets Radiobromine-Labelled Tracers for Positron Emission Tomography: Possibilities and Pitfalls
Current Radiopharmaceuticals